Live Breaking News & Updates on இன்றியமையாதது மாற்றம்

Stay updated with breaking news from இன்றியமையாதது மாற்றம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Washington takes on Big Pharma: Lower drug prices vs. fewer new cures


As drugmakers adjust to less revenue, however, it would result in eight fewer new drugs coming to the U.S. market in 10 years and up to 30 fewer new drugs over 20 years, the Congressional Budget Office said.
Drugmakers say setting an upper limit on prices in the Medicare prescription-benefit program while fining companies that don’t play ball, looks more like extortion.
“Under the bill, the government dictates where the negotiation starts and can impose a massive tax penalty on a company that doesn’t accept the government-set price. This isn’t what most people would call a ‘negotiation.’ This is a partisan bill that threatens the future development of new treatments and patient access to life-saving medicines while doing little to fix the broader affordability challenges people are facing,” said Brian Newell, spokesman for the Pharmaceutical Research and Manufacturers of America, a major industry group and lobbying force. ....

United States , United Kingdom , White House , District Of Columbia , Juliette Cubanski , Carolyn Maloney , Henry Connelly , David Mitchell , Nancy Pelosi , Brian Newell , Charles River Associates , Kaiser Family Foundation , House Oversight Committee , Council Of Economic Advisers , Washington Times , Congressional Budget Office , Pharmaceutical Research , Economic Advisers , President Trump , Affordable Drugs , Oversight Committee Chairwoman Carolyn Maloney , Speaker Nancy Pelosi , Vital Transformation , Affordable Care Act , Memorial Day , B Health Medical Pharma ,

H.R. 3's international reference pricing misses the mark


H.R. 3’s international reference pricing misses the mark
By Susan Peschin
Adobe
The White House and Congress have declared that reining in Medicare prescription drug costs to help older adults and people with disabilities is a top priority. But one drug pricing strategy on the table would have an outsized negative impact on people with Alzheimer’s disease and decimate research trying to find effective treatments for it.
This strategy, known as international reference pricing, ties the price that Medicare pays for some drugs to those paid by other countries. The idea was first introduced as a model for Medicare Part B drugs by then-HHS Secretary Alex Azar in 2018. The next year, House Speaker Nancy Pelosi’s drug pricing plan, known as the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3), significantly expanded the scope to allow federal government use of foreign price controls in direct negotiations with pharmaceutical companies for the cost of 250 prescr ....

United States , United Kingdom , White House , District Of Columbia , Alex Azar , Nancy Pelosi , Elijahe Cummings , Democratic National Committee , Alliance For Aging Research , National Institutes Of Health , National Council On Disability , Congressional Budget Office , House Speaker Nancy Pelosi , Lower Drug Costs Now Act , National Council , Affordable Care Act , Rehabilitation Act , National Institutes , Vital Transformation , Aging Research , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , வெள்ளை வீடு , மாவட்டம் ஆஃப் கொலம்பியா , அலெக்ஸ் அசார் , நான்சி பெளோஸி ,